Merck, Inc.
🇺🇸United States
Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045)
Phase 1
Completed
- Conditions
- Human Immunodeficiency Virus (HIV) Infection
- Interventions
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT02715700
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)
Phase 2
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2016-03-08
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 156
- Registration Number
- NCT02702414
Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)
Phase 3
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Biological: PembrolizumabDrug: PlaceboOther: Best Supportive Care
- First Posted Date
- 2016-03-08
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 413
- Registration Number
- NCT02702401
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
Phase 1
Terminated
- Conditions
- AML Including AML de Novo and AML Secondary to MDSDLBCL
- Interventions
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 9
- Registration Number
- NCT02698189
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)
Phase 1
Terminated
- Conditions
- Triple Negative Breast Cancer (TNBC)Castration-resistant Prostate Cancer (CRPC)NUT Midline Carcinoma (NMC)Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 13
- Registration Number
- NCT02698176
Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 75
- Registration Number
- NCT02684617
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
Phase 3
Active, not recruiting
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 304
- Registration Number
- NCT02684292
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)
Phase 2
Completed
- Conditions
- Ovarian Neoplasms
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 376
- Registration Number
- NCT02674061
A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT02666352
Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)
- First Posted Date
- 2016-01-22
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02661126
© Copyright 2025. All Rights Reserved by MedPath